| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5588367 | Metabolism | 2017 | 33 Pages |
Abstract
These data demonstrate that a SCAP siRNA-LNP improved the lipid profile in a clinically relevant preclinical disease model and provide evidence for SCAP inhibition as a therapy for diabetic dyslipidemic patients.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Beth Ann Murphy, Marija Tadin-Strapps, Kristian Jensen, Robin Mogg, Andy Liaw, Kithsiri Herath, Gowri Bhat, David G. McLaren, Stephen F. Previs, Shirly Pinto,